Lupin launches second generic drug this week
Indian pharma major Lupin updated that it has launched Clobazam Oral Suspension 2.5/mg which has already got the USFDA approval in the US market.
The company launched Clobazam Oral Suspension, 2.5mg/mL, for which it had received the United States Food and Drug Administration (USFDA) approval earlier. The product is a generic version of Lundbeck Pharmaceuticals LLC's Onfi Oral Suspension, 2.5mg/ml. It is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older. Clobazam Oral Suspension, 2.5mg/mL had annual sales of US$253 million in the US (IQVIA MAT December 2018).
The launch was followed by another launch of Tadalafil Tablets USP 20mg during the same week, on 12 February 2019. Tadalafil Tablets, 20mg (RLD: Adcirca) had annual sales of approximately US$474.3 million in the US.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs, globally.
On Friday, the stock closed at per share price of Rs. 775.80 which was down by 4.32 per cent. The benchmark index BSE Sensex closed with a loss of 67 points at 35,808.95.